Jervell-Lange Nielsen syndrome (JLNS) with autosomal recessive inheritance is a congenital cardiovascular disorder characterized by prolongation of QT interval on the ECG and deafness. We have performed molecular investigation by haplotype analysis and DNA Sanger sequencing in 2 unrelated Iranian families with a history of syncope. Mutational screening of KCNQ1 gene revealed the novel homozygous frameshift mutation c.733-734delGG (p.G245Rfs*39) in 2 obviously unrelated cases of JLNS which is probably a founder mutation in Iran. The novel mutation detected in this study is the first time reported among Iranian population and will be beneficial in the tribe and region-specific cascade screening of LQTS in Iran. 
| INTRODUCTION
The congenital long-QT syndrome (LQTS), a prolongation of the QT interval at electrocardiogram (ECG), is a severe cardiac arrhythmia. 1 Inherited LQTS have been characterized in 2 forms: autosomal-dominant Romano-Ward syndrome (RWS) and Jervell-Lange Nielsen syndrome (JLNS). Romano-Ward syndrome (MIM# 192500 ) is the most common form of inherited LQTS, with an estimated incidence of 1:5000-1:10 000 live births. JLNS (MIM# 220400) is less prevalent (1:50.000). In these patients, LQTS is associated with congenital sensorineural deafness, and the pattern of inheritance is autosomal recessive. 2 In 1993, Schwartz et al 3 developed the diagnostic criteria for clinical diagnosis of LQTS that is essential to identify asymptomatic carriers. LQTS is characterized by some features including extended QT interval and T-wave alteration in ECG, syncope, ventricular tachycardia (VT), torsade de points (TdP) and an increased risk of sudden death due to TdP or VT. 4 So far, a panel of sixteen candidate genes has been known that heterozygous mutations in them cause Romano-Ward syndrome and mainly 2 genes that 
The first proband was a 5-year-old boy who was referred to our center due to syncope. The medical history showed recurrent bradycardia during the fetal period, syncope, and cochlear implantation at 4 for management of sensory-neural hearing loss. There was no family history of syncope, faint or sudden death in 5 generations. In the paraclinical studies, the level of electrolytes and hormone analysis was in normal range. Resting 12-lead electrocardiogram (ECG) displayed a manifestly prolonged QTc interval of more than 600 ms (corrected by Bazett's formula) and T-wave alternant ( Figure 1A ).
Also, a structurally normal heart was detected by echocardiography report. The ECG of his asymptomatic parents showed a totally normal electrocardiogram. Propranolol with the dose of 3 mg/kg/d, divided 3 times a day, was started for the patient. An endocardial single-chamber implantable cardioverter defibrillator (ICD) was implanted to prevent any life-threatening events.
| Patient 2
The proband was a 3-year girl with recurrent syncopes and congenital neurosensory deafness. She had a QTc interval of 540-560 ms (corrected by Bazett's formula) and T-wave alternant on V1-V4 (Figure 1B) . She had a history of fainting, while she was in the bath and during exercise. Her first syncope episode had occurred at
| DISCUSSION
Long-QT syndrome includes a variety of diseases caused by mutations in cardiac ion channels. Among the genes encoding ion channels of the heart, homozygous or compound heterozygous mutations in KCNQ1 and KCNE1 genes are responsible for the recessive type of LQTS known as JLNS. These 2 genes encode subunits responsible for a voltage-gated potassium channel formation, as the potassium current is the fundamental part of the cardiac repolarization and normal function of inner ear cells. In addition, it has an essential role to speed up the activating potassium current (IKs). 14, 15 Mutations in either the KCNQ1 or KCNE1 genes affect potassium transport in the inner ear and cardiac muscle, causing deafness and an irregular heart rhythm. of KCNQ1. As C loops are critical in modifying the function of voltage-gated potassium channels, changing the C loop residues by mutations in this area of KCNQ1 gene, effects on the voltage dependence of channel activation, leads to increased risk for lethal cardiac events. 18 Although functional assays of mutation were not conducted in these patients, however frameshift mutations, with an estimated predicted value (EPV) of 99%, were expected to have a pathogenic effect. 19 Electrophysiological study revealed that mutations in the S4-S5
linker, W248R, and E261K, changed the voltage dependence of KCNQ1 channels and caused deactivation of KCNQ1. 20 It has been reported that missense mutations in the S4-S5 linker, V254M, led to F I G U R E 1 ECG of the patients. A, The 12-lead electrocardiogram of the patient A at 5 years of age demonstrating prolonged QTc interval (QTc>600 ms, heart rate: 62 beats/min) and T-wave alternancy. B, The 12-lead electrocardiogram of the patient B at 3 years of age demonstrating prolonged QTc interval; QTc>520 ms, heart rate: 72 beats/min (with a paper speed of 25 mm/s and 10 mm/mV at 20 Hz) loss of function; however, mutant subunits along with the wild-type KCNQ1 expedited the ratio of channel activation. 21 Therefore, as Sanguinetti et al 22 described, such as KCNH2, missense mutations in the S4-S5 linker of KCNQ1 can either slack or expedite channel activation. 20 Moreover, other functional assay demonstrated that mutations in C loops of KCNQ1 gene, in the absence 23 and presence of wild-type subunits, significantly impressed adrenergic channel regulation. 24 As JLNS patients tend to have mutations that cause frameshifts 25 and/or protein truncation 26 and it was suggested that truncating mutations result in loss of function, 27 in this report, support for this concept is provided. In both families, a frameshift mutation is present, with the truncating mutation leading to QT prolongation in affected individuals. In 2006, one report presented the guidelines that suggested an experimental b-blockers therapy in all LQTS patients, 28 meanwhile another study proved the effect of beta-blockers on affected individuals who have mutations in the C loops collated with mutations in another location that can decline the risk of lethal cardiac incidents. 24 According to previous studies, 6 patients with JLNS carrying KCNQ1 mutations are at particularly high risk, and therefore, special aids, including beta-blocker therapy, may be supposed necessary because of the high recurrence rate of fatal arrhythmia. Both of our cases were treated with propranolol or in one instance ICD. During 1 year using propranolol therapy follow-up of these patients, any cardiac events were recorded. Unfortunately, although Left cardiac sympathetic denervation (LCSD) helps to reduce life-treating events in such cases, but we did not do it nowadays in our centers.
G245Rfs*39 mutation in LQTS patients has not been previously reported and appears to be a novel mutation. This mutation deletes | 289
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